Ultragenyx Pharmaceutical's total assets for Q1 2025 were $1.31B, a decrease of -12.74% from the previous quarter. RARE total liabilities were $1.16B for the fiscal quarter, a -6.48% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.